Department of Oncology, Vejle Hospital, Vejle, Denmark.
J Ovarian Res. 2012 Sep 19;5(1):23. doi: 10.1186/1757-2215-5-23.
Anti-VEGF treatment has proven effective in recurrent ovarian cancer. However, the identification of the patients most likely to respond is still pending. It is well known that the angiogenesis is regulated by several other pro-angiogenic proteins, e.g. the platelet - derived growth factor (PDGF) system and the fibroblast growth factor (FGF) system. These other signaling pathways may remain active or become upregulated during anti-VEGF treatment.The aim of the present study was to investigate if potential changes of PDGF-BB, PDGF-AA, and FGF2 before and during bevacizumab treatment had predictive value for early progression or survival. Furthermore, we wanted to investigate the importance of serum VEGF in the same cohort.
This study included 106 patients with chemotherapy-resistant epithelial ovarian cancer who were treated with single agent bevacizumab as part of a biomarker protocol. Patients were evaluated for response by the Response Evaluation Criteria In Solid Tumors (RECIST) and/ or Gynecologic Cancer Intergroup (GCIG) CA125 criteria. Serum samples were collected at baseline and prior to each treatment. FGF2, PDGF-BB, PDGF-AA were quantified simultaneously using the Luminex system, and VEGF-A was measured by ELISA. Eighty-eight baseline samples were avaliable for FGF2, PDGF-BB, PDGF-AA analysis, and 93 baseline samples for VEGF.
High baseline serum VEGF was related to poor overall survival. Furthermore, high serum PDGF-BB and FGF2 was of prognostic significance. None of the markers showed predictive value, neither at baseline level nor during the treatment.
抗血管内皮生长因子（VEGF）治疗已被证明对复发性卵巢癌有效。然而，识别最有可能受益的患者仍然悬而未决。众所周知，血管生成受多种其他促血管生成蛋白调节，如血小板衍生生长因子（PDGF）系统和纤维母细胞生长因子（FGF）系统。这些其他信号通路在抗 VEGF 治疗期间可能仍然活跃或上调。本研究旨在探讨贝伐珠单抗治疗前后 PDGF-BB、PDGF-AA 和 FGF2 的潜在变化是否对早期进展或生存具有预测价值。此外，我们还希望在同一队列中研究血清 VEGF 的重要性。
这项研究包括 106 名接受单药贝伐珠单抗治疗的化疗耐药上皮性卵巢癌患者，这些患者是作为生物标志物方案的一部分接受治疗的。通过实体瘤反应评估标准（RECIST）和/或妇科肿瘤学组（GCIG）CA125 标准评估患者的反应。在基线和每次治疗前采集血清样本。使用 Luminex 系统同时定量检测 FGF2、PDGF-BB 和 PDGF-AA，使用 ELISA 检测 VEGF-A。有 88 份基线样本可用于 FGF2、PDGF-BB 和 PDGF-AA 分析，93 份基线样本可用于 VEGF。
高基线血清 VEGF 与总生存期不良相关。此外，高血清 PDGF-BB 和 FGF2 具有预后意义。在基线水平或治疗期间，这些标志物均无预测价值。
